E M Antman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Time is muscle: translation into practice
    Elliott M Antman
    Cardiovascular Division, TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 52:1216-21. 2008
  2. ncbi request reprint Cyclooxygenase inhibition and cardiovascular risk
    Elliott M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 112:759-70. 2005
  3. ncbi request reprint The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
    E M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 284:835-42. 2000
  4. ncbi request reprint Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction
    Elliott M Antman
    TIMI Study Group and the Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:229-34. 2002
  5. ncbi request reprint Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass, USA
    Circulation 105:1642-9. 2002
  6. ncbi request reprint Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
    Elliott M Antman
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:217-26. 2005
  7. doi request reprint Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Elliott M Antman
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2028-33. 2008
  8. ncbi request reprint Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 100:1602-8. 1999
  9. ncbi request reprint Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 100:1593-601. 1999
  10. ncbi request reprint Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:2604-7. 2003

Collaborators

Detail Information

Publications120 found, 100 shown here

  1. doi request reprint Time is muscle: translation into practice
    Elliott M Antman
    Cardiovascular Division, TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 52:1216-21. 2008
    ..By focusing now on system efforts for improvements in timely care for STEMI, we will complete the cycle of research initiated by Reimer and Jennings 30 years ago. Time is muscle ... we must translate that into practice...
  2. ncbi request reprint Cyclooxygenase inhibition and cardiovascular risk
    Elliott M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 112:759-70. 2005
  3. ncbi request reprint The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
    E M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 284:835-42. 2000
    ..Patients with unstable angina/non-ST-segment elevation myocardial infarction (MI) (UA/NSTEMI) present with a wide spectrum of risk for death and cardiac ischemic events...
  4. ncbi request reprint Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction
    Elliott M Antman
    TIMI Study Group and the Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:229-34. 2002
    ....
  5. ncbi request reprint Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass, USA
    Circulation 105:1642-9. 2002
    ..ENTIRE-TIMI 23 evaluated enoxaparin with full-dose tenecteplase (TNK) and half-dose TNK plus abciximab...
  6. ncbi request reprint Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
    Elliott M Antman
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:217-26. 2005
  7. doi request reprint Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Elliott M Antman
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2028-33. 2008
    ....
  8. ncbi request reprint Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 100:1602-8. 1999
    ..A prospectively planned meta-analysis was performed to provide a more precise estimate of the effects of enoxaparin on multiple end points...
  9. ncbi request reprint Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 100:1593-601. 1999
    ..Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH) for management of unstable angina/non-Q-wave myocardial infarction (UA/NQMI)...
  10. ncbi request reprint Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:2604-7. 2003
  11. ncbi request reprint Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    Elliott M Antman
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 354:1477-88. 2006
    ..Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose...
  12. ncbi request reprint Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators
    E M Antman
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 21:1944-53. 2000
    ..reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously for reduced doses of reteplase without abciximab and were at least as high as for full dose reteplase alone..
  13. ncbi request reprint Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy
    E M Antman
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:326-30. 1998
    ..We sought to determine whether the rapid bedside assay for troponin T identified patients at risk for a more complicated hospital stay and a higher rate of adverse clinical events...
  14. ncbi request reprint Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 134:622-30. 1997
    ..The availability of a reliable, noninvasive serum marker of reperfusion may permit early identification of patients with occlusion after thrombolysis who might benefit from further interventions...
  15. ncbi request reprint Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II
    R P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 22:1702-15. 2001
    ..These findings have important implications in the design and interpretation of international studies, identify under- and over-utilized therapies, and support further study of treatments with marked worldwide variations...
  16. ncbi request reprint TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:2031-7. 2000
    ..Complex multivariable models identify independent predictors and quantify their relative contribution to mortality risk but are too cumbersome to be readily applied in clinical practice...
  17. ncbi request reprint Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial
    J A de Lemos
    Cardiovascular Division, Brigham and Women s Hospital, Boston Massachusetts, USA
    Circulation 101:239-43. 2000
    ..We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation...
  18. ncbi request reprint Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
    R P Giugliano
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 141:742-50. 2001
    ..The optimal heparin dose as an adjunct to fibrinolysis and its role in causing intracranial hemorrhage (ICH) is unclear...
  19. ncbi request reprint Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 34:739-47. 1999
    ....
  20. ncbi request reprint Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy
    J A de Lemos
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Chim Acta 298:85-97. 2000
    ..Despite a favorable kinetic profile, however, H-FABP does not appear to represent a significant advance over myoglobin in the noninvasive detection of reperfusion after thrombolysis...
  21. ncbi request reprint Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
    J A de Lemos
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 140:373-8. 2000
    ..We evaluated the combination of a baseline myoglobin assay and early (60- to 90-minute) ST resolution for risk stratification after ST-segment elevation myocardial infarction...
  22. ncbi request reprint Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time
    G E Bozovich
    Favaloro Foundation, Buenos Aires, and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am Heart J 140:637-42. 2000
    ..Whether the clinical superiority of enoxaparin versus unfractionated heparin (UFH) depends on a more stable antithrombotic effect or the proportion of patients not reaching the therapeutic level with UFH has not been addressed...
  23. ncbi request reprint Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Circulation 103:2550-4. 2001
    ..These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI...
  24. ncbi request reprint Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience)
    M J Schweiger
    Department of Medicine, Baystate Medical Center, Springfield, Massachusetts 01199, USA
    Am J Cardiol 88:831-6. 2001
    ..e., TIMI 3 flow at 90 minutes) who did not undergo revascularization (p = 0.02). Thus, early PCI following AMI is associated with excellent outcomes. Randomized trials of an early invasive strategy following thrombolysis are warranted...
  25. ncbi request reprint C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:1460-5. 1998
    ....
  26. ncbi request reprint An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 23:223-9. 2002
    ..We evaluated the TIMI Risk Score for Unstable Angina and Non-ST Elevation Myocardial Infarction for predicting clinical outcomes and the efficacy of tirofiban in non-ST elevation acute coronary syndromes...
  27. ncbi request reprint Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 35:358-62. 2000
    ....
  28. ncbi request reprint Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group
    C M Gibson
    Department of Medicine, The University of California San Francisco, 94118, USA
    Am J Cardiol 87:450-3, A6. 2001
    ..Thus, the 60-minute angiographic end point appears to be a valid alternative to that at 90 minutes and may permit earlier decisions regarding post-thrombolytic intervention...
  29. ncbi request reprint A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy
    D A Morrow
    TIMI Trials Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 358:1571-5. 2001
    ..Available models for predicting mortality in STEMI include up to 45 variables, but have consistently shown advanced age, increased heart rate, and decreased blood pressure to be among the strongest predictors...
  30. doi request reprint Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 27:11-7. 2009
    ....
  31. ncbi request reprint Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction
    J Llevadot
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 22:2104-15. 2001
    ..There is a need for additional randomized trials in the current era to address both the appropriate selection of patients and timing of invasive procedures in ST-elevation acute myocardial infarction...
  32. ncbi request reprint Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy
    D A Morrow
    Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 36:1812-7. 2000
    ....
  33. ncbi request reprint Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 46:453-60. 2000
    ..Until adequate cTnI standardization is possible, an evidence-based approach evaluating each assay at specific thresholds appears warranted...
  34. ncbi request reprint Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy
    V S Srinivas
    Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
    Am Heart J 142:29-36. 2001
    ..A low 12-hour myoglobin level (< or = 239 ng/mL in this substudy) identifies such patients at low risk and could potentially assist in early risk stratification and triage after ST-segment elevation myocardial infarction...
  35. ncbi request reprint Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
    ..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study...
  36. ncbi request reprint Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum
    E M Antman
    Samuel L Levine Cardiac Unit, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 139:461-75. 2000
    ..In the past 5 years, rapid progress has been made in the management of patients with unstable coronary syndromes, yet current guidelines do not necessarily reflect these advances...
  37. ncbi request reprint Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
    Catheter Cardiovasc Interv 53:6-11. 2001
    ....
  38. ncbi request reprint Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3
    D A Morrow
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:1356-9. 2001
    ..Developed and validated in multiple clinical trials of fibrinolysis, the risk score has not been validated in a community-based population...
  39. ncbi request reprint Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  40. ncbi request reprint The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:89S-95S. 2003
    ..In addition, using the risk score to categorize patients also effectively defines a gradient for benefit with specific treatments such as low-molecular-weight heparins, glycoprotein IIb/IIIa inhibitors, and an early invasive strategy...
  41. ncbi request reprint Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  42. doi request reprint Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  43. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  44. ncbi request reprint Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction
    Masahisa Shimpo
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 109:2186-90. 2004
    ..Serum levels of ST2 are associated with prognosis in nonischemic heart failure, but the predictive value of ST2 in patients with acute myocardial infarction is unknown...
  45. ncbi request reprint Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II
    E M Antman
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 23:928-33. 2002
    ..When evaluating new reperfusion regimens for ST elevation MI, it is important to adjust for factors that influence the likelihood of achieving normal epicardial flow and complete ST resolution...
  46. ncbi request reprint Bolus fibrinolytic therapy in acute myocardial infarction
    J Llevadot
    TIMI Study Group, 333 Longwood Ave, Suite 402, Boston, MA 02115, USA
    JAMA 286:442-9. 2001
    ..CONCLUSION: Given the ease of administration and the similar outcomes compared with accelerated infusion recombinant tPA, it is likely that a key component of contemporary reperfusion will include a bolus fibrinolytic...
  47. ncbi request reprint Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 23:308-14. 2002
    ..Interest in the use of enoxaparin would be enhanced further if evidence of a durable treatment benefit over the long term could be provided...
  48. doi request reprint Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Drugs 69:1433-43. 2009
    ....
  49. ncbi request reprint Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2256-63. 2007
    ....
  50. doi request reprint Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    Michelle L O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 374:989-97. 2009
    ..Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel...
  51. ncbi request reprint Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
    David A Morrow
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 154:1078-84, 1084.e1. 2007
    ..Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding...
  52. ncbi request reprint Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3366-73. 2005
    ..Prasugrel (CS-747, LY640315), a novel potent thienopyridine P2Y(12) receptor antagonist, has the potential to achieve higher levels of inhibition of ADP-induced platelet aggregation than currently approved doses of clopidogrel...
  53. doi request reprint Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel
    Yuri B Pride
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Interv 3:806-11. 2010
    ..This study sought to determine angiographic and clinical outcomes among patients with acute coronary syndrome (ACS) presenting with isolated anterior ST-segment depression on 12-lead electrocardiogram (ECG)...
  54. ncbi request reprint Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction
    E M Holper
    Department of Internal Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Coron Artery Dis 10:567-73. 1999
    ..Available evidence suggests that glycoprotein IIb/IIIa inhibition may facilitate thrombolysis, thus adding a new element to future reperfusion regimens...
  55. ncbi request reprint A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  56. ncbi request reprint Identification of patients at high risk for death and cardiac ischemic events after hospital discharge
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:966-70. 2002
    ..Patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) remain at risk for death and cardiac ischemic events after being discharged from the hospital...
  57. doi request reprint Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  58. ncbi request reprint Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 109:874-80. 2004
    ..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI...
  59. ncbi request reprint Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 152:627-35. 2006
    ..TRITON-TIMI 38 is designed to compare prasugrel with clopidogrel in moderate to high-risk patients with acute coronary syndrome (ACS)...
  60. doi request reprint The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Am Coll Cardiol 54:678-85. 2009
    ..We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor...
  61. ncbi request reprint Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
    ....
  62. doi request reprint Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
    Marc S Sabatine
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 374:787-95. 2009
    ..Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study...
  63. doi request reprint Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 118:1626-36. 2008
    ..We compared prasugrel with clopidogrel among subjects with DM in TRITON-TIMI 38...
  64. ncbi request reprint Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial
    Benjamin A Steinberg
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 154:54-61. 2007
    ..We hypothesized that adjustment for baseline risk would minimize such variations...
  65. ncbi request reprint Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:2238-46. 2007
    ....
  66. ncbi request reprint Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Stephen D Wiviott
    Brigham and Women s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2923-32. 2007
    ..The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown...
  67. ncbi request reprint Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  68. ncbi request reprint Clopidogrel resistance: a new chapter in a fast-moving story
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:3064-7. 2004
  69. ncbi request reprint Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction
    Juhana Karha
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 92:913-8. 2003
    ..In patients with a LAD culprit lesion, proximal lesion location is a multivariate correlate of adverse outcomes even after adjustment for coronary blood flow and other covariates...
  70. pmc Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
    Sabina A Murphy
    Department of Medicine, Cardiovascular Division, TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 29:2473-9. 2008
    ..We hypothesized that prasugrel would reduce not only first events but also recurrent primary endpoint events and therefore total events compared with clopidogrel...
  71. doi request reprint Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
    Lancet 371:1353-63. 2008
    ..We assessed the rate, outcomes, and prevention of ischaemic events in patients treated with prasugrel or clopidogrel with stents in the TRITON-TIMI 38 study...
  72. ncbi request reprint Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention
    Graham C Wong
    TIMI Study Group, Brigham and Women s Hospital, Boston, Mass 02115, USA
    JAMA 289:331-42. 2003
    ..Low-molecular-weight heparins (LMWHs) possess several potential pharmacological advantages over unfractionated heparin as an antithrombotic agent...
  73. ncbi request reprint Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality
    C Michael Gibson
    TIMI Study Chairman s Office, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Am Coll Cardiol 42:1535-43. 2003
    ..We hypothesized that impaired renal function would also be associated with poorer clinical outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis...
  74. doi request reprint Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:2553-60. 2009
    ..The effect of CYP polymorphisms on the clinical outcomes in patients treated with prasugrel remains unknown...
  75. ncbi request reprint Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial
    Sabina A Murphy
    TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 146:42-7. 2003
    ....
  76. ncbi request reprint The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies
    James A de Lemos
    Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
    J Am Coll Cardiol 40:238-44. 2002
    ..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)...
  77. ncbi request reprint The smoker's paradox: insights from the angiographic substudies of the TIMI trials
    Brad G Angeja
    Cardiovascular Division, Department of Medicine, University of California, San Francisco, USA
    J Thromb Thrombolysis 13:133-9. 2002
    ..We determined the clinical risk profiles and coronary flow characteristics of patients in the TIMI trials according to smoking status, focusing on microvascular flow...
  78. ncbi request reprint Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    Eur Heart J 28:1566-73. 2007
    ..We compared outcomes of ST-elevation myocardial infarction (STEMI) patients randomized to a strategy of either enoxaparin or unfractionated heparin (UFH) to support fibrinolysis...
  79. pmc Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 376:1312-9. 2010
    ..We also assessed the effect of genotype on the pharmacodynamic and pharmacokinetic properties of these drugs in healthy individuals...
  80. ncbi request reprint TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Am J Med 120:993-8. 2007
    ....
  81. ncbi request reprint Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 26:682-8. 2005
    ..Sunol-cH36, a chimaeric monoclonal antibody to TF, blocks binding of factor X to the TF:VIIa complex. This report describes the first completed trial of Sunol-cH36 in humans...
  82. ncbi request reprint Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes
    Robert W Yeh
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Am J Cardiol 100:1734-8. 2007
    ..In conclusion, thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH...
  83. ncbi request reprint Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 105:1760-3. 2002
    ..Little is known, however, about the utility of these biomarkers in combination...
  84. ncbi request reprint Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial
    David A Morrow
    Cardiovascular Division and TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 40:71-7. 2002
    ....
  85. doi request reprint Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Am Heart J 158:e21-6. 2009
    ..Whether this benefit extends to patients undergoing PCI without stent implantation is unknown...
  86. ncbi request reprint Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration
    Howard A Cooper
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 144:790-5. 2002
    ..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming...
  87. doi request reprint Cytochrome p-450 polymorphisms and response to clopidogrel
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 360:354-62. 2009
    ..Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function...
  88. pmc Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    JAMA 304:1821-30. 2010
    ..Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes...
  89. ncbi request reprint Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, and TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA, USA
    Am J Cardiol 95:224-7. 2005
    ..043). In multivariate analyses, angiographically evident thrombus was associated with higher corrected TIMI frame counts and worsened myocardial perfusion independent of clinical and angiographic covariates, including TIMI grade 3 flow...
  90. ncbi request reprint Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:980-7. 2004
    ....
  91. ncbi request reprint Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  92. ncbi request reprint Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
    Jessica L Mega
    TIMI Study Group, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 149:846-50. 2005
    ....
  93. ncbi request reprint Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 115:2822-8. 2007
    ..The safety and efficacy of pharmacological reperfusion therapy in women with ST-elevation myocardial infarction are of particular interest...
  94. ncbi request reprint Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
    ....
  95. ncbi request reprint A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction
    E M Antman
    Department of Medicine, Brigham and Women's Hospital, Boston, MA
    JAMA 268:240-8. 1992
    ....
  96. ncbi request reprint Acute ST-segment elevation myocardial infarction and prior stroke: an analysis from the Magnesium in Coronaries (MAGIC) trial
    Howard A Cooper
    Washington Hospital Center, Washington, DC 20010, USA
    Am Heart J 148:1012-9. 2004
    ..However, the impact of prior stroke on prognosis has not been rigorously examined in the reperfusion era...
  97. ncbi request reprint ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
    Eugene Braunwald
    Circulation 106:1893-900. 2002
  98. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  99. ncbi request reprint Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA
    Am Heart J 143:63-9. 2002
    ..To examine the mode and timing of subsequent cardiac events, we analyzed pooled data from the ESSENCE and TIMI 11B studies of antithrombotic therapy in NSTEMI ACS...
  100. ncbi request reprint ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guideli
    Eugene Braunwald
    J Am Coll Cardiol 40:1366-74. 2002
  101. ncbi request reprint Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda
    Jane A Leopold
    Circulation 111:1097-9. 2005